Real World Experience of the First Cardio-Oncology Unit Implantation in Morocco

Abstract

Cardiotoxicity presents a multifaceted challenge with significant implications. Our investigation delving into cardiotoxicity linked with Anthracyclines and Trastuzumab has shed light on these agents as frequent culprits, revealing a spectrum of cardiac complications like heart failure, arrhythmias, hypertension, QTc prolongation, and arterial and venous thromboses. However, the true prevalence of cardiotoxicity is often underestimated due to delayed effects, patient attrition post-remission, and the emergence of novel therapeutic agents. The collaboration between cardiology and oncology is expanding, encompassing Cardio-Hematology and its impact on conditions like multiple myeloma, leukemia, and lymphomas. This evolving convergence underscores the necessity for interdisciplinary collaboration. The study findings highlight the significance of adhering to guidelines while acknowledging that guidelines should serve as aids rather than substitutes for clinical judgment within multidisciplinary tumor boards (MTBs). Enhanced by ongoing research, these guidelines serve as instruments empowering clinicians to make well-informed decisions tailored to individual patient needs. Scientific research remains pivotal, guiding progress and offering promise for enhanced outcomes in the global battle against cancer.